New plavix rival enters human testing
NCT ID NCT07619885
First seen Jun 25, 2026 · Last updated Jun 30, 2026 · Updated 3 times
Summary
This early-stage trial compares a new investigational drug, CG-0255, to the established blood thinner Plavix in 136 healthy adults aged 18-55. The goal is to see if CG-0255 is processed by the body similarly to Plavix and has the same effect on preventing blood clots. Participants will receive either CG-0255 or Plavix, and researchers will measure drug levels and platelet function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CG-0255 (a prodrug similar to clopidogrel/Plavix)
- What this could lead to
- If successful, this could lead to a new option for preventing dangerous blood clots in people with heart disease or stroke risk.
- What could go wrong
- This is a very early Phase 1 study in healthy volunteers, not patients. It only measures drug levels and platelet activity, not actual clinical outcomes like heart attacks. Many drugs fail in later stages.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROMES (ACS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Syneos Health
RECRUITINGMiami, Florida, 33101, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Beetroot juice may boost heart blood flow and walking in leg artery disease
- Can a Pre-Surgery skin coating stop wound infections?
- Can a 'Scoring' balloon unclog leg arteries better and reduce stents?
- Can a temporary stent keep leg arteries open?
- Heart rehab goes hybrid: can a mix of home and clinic sessions boost adherence?
- Can a Lab-Grown artery graft outlast current options?